Financial Performance - Net profit attributable to shareholders increased by 90.77% to ¥13,813,849.51 from ¥7,241,008.50 in the same period last year[10] - Operating revenue decreased by 5.59% to ¥203,127,296.64 compared to ¥215,161,063.47 in the previous year[10] - The company's gross profit margin increased by 2.55 percentage points due to product structure adjustments[14] - Total operating revenue for Q1 2023 was ¥203,127,296.64, a decrease of 5.0% from ¥215,161,063.47 in Q1 2022[44] - Net profit for Q1 2023 reached ¥13,813,849.51, representing an increase of 91.5% compared to ¥7,241,008.50 in Q1 2022[46] - Earnings per share for Q1 2023 were ¥0.15, up from ¥0.11 in Q1 2022[46] Assets and Liabilities - Total assets decreased by 3.22% to ¥870,838,710.25 compared to the end of last year[10] - The total liabilities to assets ratio decreased to 45.90% from 49.17% at the end of the previous year[10] - Current liabilities decreased to ¥369,143,515.54 from ¥410,540,539.25, showing a reduction of about 10.1%[37] - Total liabilities decreased to ¥399,674,149.19 from ¥442,489,652.55, representing a decline of approximately 9.7%[38] - Total non-current assets decreased to ¥227,717,961.23 from ¥229,688,588.15, reflecting a reduction of about 0.9%[37] - Total cash and cash equivalents were reported at ¥9,773,542.80 as of March 31, 2023, compared to ¥133,456,308.34 on December 31, 2022, indicating a significant decrease[36] Shareholder Information - The total number of shares held by major shareholders is 70,407,940, representing 77.66% of total shares[24] - The largest shareholder, Hu Xiang, holds 40,370,207 shares, accounting for 44.53% of total shares[24] - The second-largest shareholder, Chen Yin, holds 15,907,300 shares, representing 17.54% of total shares[24] - The relationship between major shareholders includes familial ties, with Hu Xiang and Chen Yin being spouses[25] Cash Flow - Cash flow from operating activities turned positive at ¥14,974,355.06, compared to a negative cash flow of -¥4,179,599.87 in the same period last year[10] - Operating cash inflow for Q1 2023 was CNY 69,219,961.18, an increase from CNY 65,123,851.09 in Q1 2022, representing a growth of approximately 3.2%[51] - Net cash flow from operating activities for Q1 2023 was CNY 14,974,355.06, compared to a negative CNY 4,179,599.87 in Q1 2022, indicating a significant recovery[53] - Cash outflow from investing activities in Q1 2023 totaled CNY 108,549,092.15, a substantial increase from CNY 1,820,660.97 in Q1 2022, reflecting increased investment efforts[53] - Cash flow from financing activities in Q1 2023 resulted in a net outflow of CNY 30,472,269.67, compared to a net inflow of CNY 13,788,540.25 in Q1 2022, indicating a shift in financing strategy[53] Other Financial Metrics - The company's financial expenses decreased by 76.50% due to reduced loan and bill discounting scales[15] - Other income increased by 713.10% due to government subsidies received[16] - Research and development expenses for Q1 2023 were ¥6,244,397.97, slightly down from ¥6,385,189.78 in Q1 2022[45] - The company reported a financial expense of ¥167,545.45 in Q1 2023, a decrease from ¥713,018.45 in Q1 2022[45] - Deferred income tax liabilities were ¥8,103,834.35 in Q1 2023, slightly up from ¥8,043,896.21 in Q1 2022[42]
合肥高科(430718) - 2023 Q1 - 季度财报